Logo

Millennium and Wyeth Extend Central Nervous System Collaboration

Sep 10, 1999
Premium

CAMBRIDGE, Mass.--Millennium Pharmaceuticals announced that its collaboration with Wyeth-Ayerst Research in the area of central nervous system disorders will be extended for at least two more years. Millennium also revealed that it has provided Wyeth with a third novel candidate gene, the discovery of which activates an undisclosed milestone payment to Millennium. Under the original 1996 agreement, Wyeth agreed to pay Millennium up to $90 million in licensing fees and research payments to access genomic technologies and fund research, including human population genetic studies, aimed at developing novel treatments for a broad range of CNS diseases.

Filed under

Informatics
Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.